Professor Ravindra Gupta


Dr Ravindra Kupta
Dr Ravindra Kupta

Having completed his medical undergraduate studies at Cambridge and Oxford Universities, Ravi Gupta pursued a Masters in Public Health at Harvard as a Fulbright scholar. Upon return, he trained in infectious diseases in Oxford and London (UCLH, Hospital for Tropical Diseases) and completed his PhD at UCL on Lentiviral evasion of antiretrovirals and innate immune responses. He established his research group at UCL in 2011 working on genetics and biology of HIV resistance and reservoirs and was promoted to full professor in 2016. Ravi Gupta has been Professor of Clinical Microbiology at the Cambridge Institute for Therapeutic Immunology and Infectious Diseases since 2019. In 2020 he was named as one of the 100 most influential people by TIME.

Research Interests

HIV drug resistance, HIV persistence and cure, cellular biology of macrophages.

Links to online publications, articles or other work

Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Salasc F, Monit C, Innes A, Muir L, Waters L, Frater AJ, Lever AML, Edwards SG, Gabriel IH, Olavarria E, HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 2019; Apr;568(7751):244-248

Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Roman M, Giron A, Hamers R, Inzauke S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. HIV-1 drug resistance prior to initiation or re-initiation of first-line antri-retroviral therapy in low- and middle-income countries - a meta regression analysis. Lancet Infectious Diseases 2018 Mar; 18(3):346-355

Micochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RAM, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK. A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. EMBO J. 2017; Mar 1; 36(5):604-616

Micochova P, Caswell S, Taylor I, Towers GJ, Gupta RK. DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages. EMBO J 2018; 37:50-62

Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hung G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK. Occult drug resistance to thymidine analogues and multidrug resistant HIV-1 following failure of first line tenofovir-based antiretroviral regimens in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis 2017;17: 286-304.

Kugathasan R, Collier DA, Haddow LJ, El Bouzidi K, Edwards SG, Cartledge JD, Miller RF, Gupta RK. Diffuse white matter signal abnormalities on MRI are associated with HIV-1 viral escape in the central nervous system among patients with neurological symptoms. Clinical Infectious Diseases 2017; Apr 15;64(8):1059-1065

Collier DA, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK. for the ANRS 12249 TasP Study Group.  Virological Outcomes of second-line protease inhibitor based treatment for HIV-1 in a high prevalence rural South African setting - a competing risk prospective cohort analysis.  Clinical Infectious Diseases 2017; Apr 15;64(8):1006-1016

Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC, Diero L, Brooks K, Theys K, Rinke de Wit TF, Arruda M, Garcia F, Monge S, Günthard HF, Hoffmann CJ, Kanki PJ, Kumarasamy N, Kerschberger B, Mor O, Charpentier C, Todesco E, Rokx C, Gras L, Halvas EK, Sunpath H, Di Carlo D, Antinori A, Andreoni M, Latini A, Mussini C, Aghokeng A, Sonnerborg A, Ujjwal Neogi U, Fessel WJ, Agolory S, Yang C, Blanco JL, Juma JM, Smit E, Schmidt D, Watera C, Asio J, Kirungi W, Tostevin A, El-Hay T, Clumeck N, Goedhals D, van Vuuren C, Bester PA, Sabin C, Mukui I, Santoro MM, Perno CF, Hunft G, Morris L, Camacho R, de Oliveira T, Pillay D, Schulter E, Akio Murakami-Ogasawara A, Reyes-Terán G, Romero K, Avila-Rios S, Sirivichayakul S, Ruxrungtham K, Mekprasan S, Dunn D, Kaleebu P, Raizes E, Kantor R, Shafer RW, Gupta RK on behalf of the TenoRes study group. Global epidemiology of drug resistance following failure of WHO recommended first line regimens for adult HIV-1 infection - a multi-centre retrospective cohort study. Lancet Infect Dis 2016; May;16(5):565-75

Smith NMG, Micochova P, Watters SA, Aasa-Chapman M, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP, Schellekens J, Marsh SGE, McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK. Proof-of-principle for immune control of global HIV-1 reactivation in vivo.  Clinical Infectious Diseases 2015; 61(1):120-8

Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D. High rate of HIV re-supression after viral failure on first line antiretroviral therapy in the absence of switch to second line.  Clinical Infectious Diseases, 2014; Apr;58(7):1023-6

Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, Sawyer W, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Global trends in antiretroviral resistance in untreated HIV-1 infected individuals following ART roll-out in resource-limited settings: a global collaborative study and meta-regression analysis.  The Lancet 2012; 380(9849):1250-8

Gupta RK, Micochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ.  Simian Immunodeficiency Virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proceedings of the National Academy of Sciences, USA 2009; Dec8;106:20889-20894

Gupta RK, Hué S, Schaller T, Verschoor E, Pillay D and Towers GJ.  Mutation of a single residue renders human tetherin resistance to HIV-1 Vpu-mediated depletion.  PLoS Pathogens 2009 May;5(5):e1000443